The National Institutes of Health National Institute of Allergy and Infectious Diseases awarded multiple Indefinite Delivery/Indefinite Quantity contracts valued at approximately $364.5 million to support preclinical and translational vaccine development services for HIV vaccines and other candidate agents. Task orders will be issued against these IDV contracts over a seven-year ordering period to fund services including product storage and shipping, safety and immunogenicity studies, feasibility assessments, analytical development, process development, cGMP manufacturing, stability testing, fill-finish, and scientific/quality support.
An initial task order of $2.6 million was awarded to Technical Resources International, Inc. for guaranteed minimum contract funding, to be performed in Westlake, Maryland through August 2029. Task Area G for scientific, quality, and regulatory support services was set aside for small business concerns. Services will support the full range of preclinical and translational activities, from initial product discovery through cGMP manufacturing and clinical readiness. The original solicitation sought proposals for multiple IDV contracts to rapidly support vaccine development gaps and advance products into clinical testing for HIV and other pathogens.
Generated 1/4/24, 9:42 PM